J9153
J9153 – Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 1 NDC crosswalked per 1 MG/2.27 MG $272.886/unit ASP+6%
📋 J9153 summary
J9153 is a HCPCS Level II J-code used to bill liposomal, 1 mg daunorubicin and 2.27 mg cytarabine, billed per 1 MG/2.27 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9153: Vyxeos
Code J9153
Billing unit 1 MG/2.27 MG Payment limit $272.886/unit NDC-Crosswalk 1
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9153
DescriptorInjection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
Billing unit1 MG/2.27 MG
Payment limit / unit$272.886
Est. ASP / unit$257.440 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20
💊 About Daunorubicin DRUG GUIDE
Daunorubicin Hydrochloride Injection is used to help bring about remission — meaning a significant reduction or disappearance of leukemia cells — in people with certain types of leukemia.
It is always given in combination with other approved anticancer drugs, not alone.Specifically, it is approved for remission induction in acute nonlymphocytic leukemia (including the myelogenous, monocytic, and erythroid subtypes) in adults, and for remission induction in acute lymphocytic leukemia in both children and adults.
Clinical overview from our editorial drug guide for Daunorubicin. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$272.886
Est. ASP / unit
$257.440 est.
Est. after 2% sequester
$267.428
HCPCS dosage
1 MG/2.27 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2019-01-01
Date added2019-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9153 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9153 WITH EST. MEDICARE PAY
1 NDC map to J9153. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($272.886/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 68727-0745-02 | VYXEOS (daunorubicin and cytarabine) liposome 100 mg/20mL; 44 mg/20mL INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION | Jazz | 40 mL in 1 CARTON (68727-745-02) | 100 mg/20mL; 44 mg/20mL | 88 | $24,013.97 | — | ● Active | CMS ASP |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$599K
Claims
22
Beneficiaries
12
Spend / beneficiary
$49,918.51
Spend / claim
$27,228.28
Trend by period
Where J9153 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #420 of 824
#415
AMNIO-MAXX OR LITE P... Q4239
$644.5K
#416
KEDRAB 90377
$641.8K
#417
CAREPATCH PER SQ CM*... Q4236
$638.5K
#418
TRI MEMBRANE WRAP, P... Q4344
$610.6K
#419
TRIVISC J7329
$610K
#420
VYXEOS J9153
$599K
#421
QUZYTTIR J1201
$595.7K
#422
CYGNUS MATRIX, PER S... Q4199
$586.2K
#423
GLUCAGEN* J1610
$585.2K
#424
NOVOEIGHT J7182
$581.9K
#425
NUZYRA J0121
$578.1K
Total claims — #778 of 824
#773
DAPTOMYCIN-0.9% NACL J0874
23
#774
BREVIBLOC* J1805
23
#775
DAPTOMYCIN(J0873) J0873
22
#776
TRETTEN J7181
22
#777
REBINYN J7203
22
#778
VYXEOS J9153
22
#779
ACETADOTE* J0132
21
#780
AMPHOTERICIN B J0285
21
#781
BENTYL* J0500
21
#782
SIGNIFOR LAR J2502
21
#783
AFSTYLA J7210
21
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $599K | 12 | 22 | $49,918.51 | $27,228.28 |
| 2025 (Q1-Q4) | $5.32M | 86 | 224 | $61,804.37 | $23,728.46 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$943.3K
Medicare paid
$747.2K
Submitted services
7,701
Denial rate
46.9%
Allowed / service
$230.69
Submitted charges
$2.3M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9153 billing FAQ
What is HCPCS code J9153?
J9153 is a HCPCS Level II J-code used to bill Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9153?
One unit of J9153 represents 1 MG/2.27 MG. Report the number of units equal to the dose administered divided by 1 MG/2.27 MG.
How many units of J9153 should I bill?
Divide the dose administered by the code's unit size (1 MG/2.27 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9153?
The Medicare Part B payment limit is $272.886 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $267.428 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9153?
1 NDC currently map to J9153 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9153 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.